You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
錦欣生殖(1951.HK):收購全國最大民營單體婦兒醫療機構 完善全生命週期服務
格隆匯 10-19 17:27

10月19日,錦欣生殖醫療集團有限公司(以下簡稱錦欣生殖)發佈公吿收購四川錦欣婦女兒童醫院(以下簡稱錦欣婦兒)的業務股權。 收購交易完成後, 錦欣生殖將持有錦欣婦兒的100% 的股權。這是錦欣生殖繼今年6月收購雲南九洲醫院及和萬家醫院以來的又一大收購動作,也是錦欣生殖自上市以來的最大收購。此舉將成為錦欣生殖完善全生命週期服務的重大戰略佈局。

錦欣婦兒,總部位於四川成都,擁有70年的是全國最大的民營單體婦兒三甲醫院,其業務涵蓋產科、新生兒住院、月子、產康、兒童保健五大領域。目前該機構擁有/管理的醫療機構所承接的新生兒總出生量自2018年以來連續在成都排名前三,總分娩量佔成都市總量的約10%,錦欣婦兒總建築面積約為18,000平方米,牀位602張,門診量每年平均600,000人次。

錦欣婦兒憑藉其強大品牌認知度,優質的服務體驗以及強大的醫療規模和管理能力具有獨特的行業競爭優勢。此外,錦欣婦兒通過針對具有消費能力的中高收入人羣提供差異化服務,併為高齡或者具有特定風險的產婦提供產前篩查服務,為公司帶來額外收入貢獻。

錦欣生殖是中國輔助生殖行業的民營龍頭機構,業務涵蓋輔助生殖服務、管理服務、輔助醫療服務三塊,其中輔助生殖服務是公司的核心業務。

錦欣生殖和錦欣婦兒同屬於錦欣集團,擁有共同的文化價值觀。此次收購也體現了錦欣大股東將優質資產植入上市體系的決心,以及大股東對上市公司業務的長期看好。同時,此次收購後,大股東利益將充分綁定,且在未來有希望進一步加強。截至2021年10月19日,錦欣生殖股價為12.74港元,處於低位。據瞭解,大股東表示陸續可能會有增持的安排。

錦欣生殖首席執行官董陽表示:“本次交易的估值屬於龍頭醫療服務中最合理的。此次收購完成後,錦欣生殖有望實現7億元人民幣左右的利潤,考慮武漢、昆明等孵化業務以及公司的自然增速,可以為市場帶來足夠的上行空間。”

收購完成後,錦欣生殖將提供備孕、懷孕、產檢、分娩及產後一體化的健康管理和升級服務,以一站式服務更好地滿足客户對婦兒類產品及服務的需求。本次錦欣生殖在其紮根最深的四川通過引入強大的婦兒產業能力完善其全生命週期服務,從而進一步強化其區域競爭力及在行業的領導地位。

此次收購將釋放產業協同效應, 進一步深化錦欣生殖的行業整合能力。 未來,公司也將以整合後的成都地區業務為範本, 複製擴展到全國其他區域, 從而進一步提高優質輔助生殖和婦兒服務的可及性,助力中國生育政策的落地。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account